Cerebral sinus thrombosis in a patient with humoral immunodeficiency on intravenous immunoglobulin therapy: A case report

被引：5

作者：

Barada, W. ^{[1
]}

Muwakkit, S.

Hourani, R.

Bitar, M.

Mikati, M.

机构：

[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Div Neurol, Beirut, Lebanon

来源：

NEUROPEDIATRICS | 2008年 / 39卷 / 02期

关键词：

dural sinus thrombosis; intravenous immunoglobulins; Bruton's disease;

D O I：

10.1055/s-2008-1077088

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

We present the case of an 11-year-old boy with humoral immunodeficiency on monthly intravenous immunoglobulins (IVIG) infusions, evaluated for recurrent, brief, neurological deficits secondary to cerebral sinus thrombosis without any identifiable hypercoagulability state. Etiologic possibilities for the thrombotic event are presented with special discussion of IVIG-related cerebral thrombosis. To the best of our knowledge, our patient represents the first reported case of Bruton's disease on IVIG therapy developing a cerebral ischemic event and the second reported case of cerebral sinus thrombosis associated with IVIG use for any disease. Potential concerns regarding the risk of cerebral thrombosis during IVIG therapy in this and other disorders are reviewed.

引用

页码：131 / 133

页数：3

共 12 条

[1] Importance of anatomical asymmetries of transverse sinuses: an MR venographic study [J].

Alper, F ;

Kantarci, M ;

Dane, S ;

Gumustekin, K ;

Onbas, O ;

Durur, I .

CEREBROVASCULAR DISEASES, 2004, 18 (03) :236-239

[2] The clinical features of 16 cases of stroke associated with administration of IVIg [J].

Caress, JB ;

Cartwright, MS ;

Donofrio, PD ;

Peacock, JE .

NEUROLOGY, 2003, 60 (11) :1822-1824

[3] HIGH-DOSE INTRAVENOUS IMMUNOGLOBULIN AND SERUM VISCOSITY - RISK OF PRECIPITATING THROMBOEMBOLIC EVENTS [J].

DALAKAS, MC .

NEUROLOGY, 1994, 44 (02) :223-226

[4] Strokes, thromboembolic events, and IVIg - Rare incidents blemish an excellent safety record [J].

Dalakas, MC ;

Clark, WM .

NEUROLOGY, 2003, 60 (11) :1736-1737

[5] Transverse sinus thrombosis and IVIg treatment: a case report and discussion of risk-benefit assessment for immunoglobulin treatment [J].

Evangelou, N ;

Littlewood, T ;

Anslow, P ;

Chapel, H .

JOURNAL OF CLINICAL PATHOLOGY, 2003, 56 (04) :308-309

[6]

*FDA, 2002, INT STAT REG IMM GLO

[7] Thromboembolic events as an emerging adverse effect during high-dose intravenous immunoglobulin therapy in elderly patients: a case report and discussion of the relevant literature [J].

Hefer, D ;

Jaloudi, M .

ANNALS OF HEMATOLOGY, 2004, 83 (10) :661-665

[8] Advances in immunology: Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. [J].

Kazatchkine, MD ;

Kaveri, SV .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (10) :747-755

[9] Cerebral infarction after high-dose intravenous immunoglobulin therapy for Kawasaki disease [J].

Wada, Y ;

Kamei, A ;

Fujii, Y ;

Ishikawa, K ;

Chida, S .

JOURNAL OF PEDIATRICS, 2006, 148 (03) :399-400

[10]

Wolberg AS, 2000, AM J HEMATOL, V65, P30, DOI 10.1002/1096-8652(200009)65:1<30::AID-AJH5>3.3.CO

← 1 2 →